Cericlamine

Cericlamine (also known as JO-1017) is a drug developed by the pharmaceutical company Janssen Pharmaceutica. It was initially developed as an antidepressant, but its development was discontinued due to lack of efficacy.

History

Cericlamine was first developed by Janssen Pharmaceutica, a Belgium-based pharmaceutical company. The drug was initially developed as an antidepressant, but its development was discontinued due to lack of efficacy.

Pharmacology

Cericlamine is a reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine, three neurotransmitters known to play key roles in mood regulation. It also acts as a NMDA receptor antagonist, which may contribute to its antidepressant effects.

Clinical trials

Cericlamine has undergone several clinical trials for the treatment of major depressive disorder. However, the results of these trials were not promising, and the drug's development was discontinued.

Side effects

The most common side effects of cericlamine include nausea, vomiting, dizziness, and insomnia. In rare cases, it can cause serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, rapid heartbeat, and high body temperature.

See also

• List of investigational antidepressants
• List of withdrawn drugs

Cericlamine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia